» Articles » PMID: 33526926

Cell-based Strategies for IVD Repair: Clinical Progress and Translational Obstacles

Overview
Specialty Rheumatology
Date 2021 Feb 2
PMID 33526926
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Intervertebral disc (IVD) degeneration is a major cause of low back pain, a prevalent and chronic condition that has a striking effect on quality of life. Currently, no approved pharmacological interventions or therapies are available that prevent the progressive destruction of the IVD; however, regenerative strategies are emerging that aim to modify the disease. Progress has been made in defining promising new treatments for disc disease, but considerable challenges remain along the entire translational spectrum, from understanding disease mechanism to useful interpretation of clinical trials, which make it difficult to achieve a unified understanding. These challenges include: an incomplete appreciation of the mechanisms of disc degeneration; a lack of standardized approaches in preclinical testing; in the context of cell therapy, a distinct lack of cohesion regarding the cell types being tested, the tissue source, expansion conditions and dose; the absence of guidelines regarding disease classification and patient stratification for clinical trial inclusion; and an incomplete understanding of the mechanisms underpinning therapeutic responses to cell delivery. This Review discusses current approaches to disc regeneration, with a particular focus on cell-based therapeutic strategies, including ongoing challenges, and attempts to provide a framework to interpret current data and guide future investigational studies.

Citing Articles

Reprogramming to restore youthful epigenetics of senescent nucleus pulposus cells for mitigating intervertebral disc degeneration and alleviating low back pain.

Ma W, Wang W, Zhao L, Fan J, Liu L, Huang L Bone Res. 2025; 13(1):35.

PMID: 40075068 PMC: 11903667. DOI: 10.1038/s41413-025-00416-1.


Multiscale mechanical-adapted hydrogels for the repair of intervertebral disc degeneration.

Cai W, Yang F, Yang C, Liu Y, Xu H, Zhang W Bioact Mater. 2025; 48:336-352.

PMID: 40060142 PMC: 11889691. DOI: 10.1016/j.bioactmat.2025.02.021.


1,25(OH)₂D₃ inhibits ferroptosis in nucleus pulposus cells via VDR signaling to mitigate lumbar intervertebral disc degeneration.

Li Q, Peng J, Ding F Sci Rep. 2025; 15(1):7968.

PMID: 40055439 PMC: 11889087. DOI: 10.1038/s41598-025-92405-x.


Designing hydrogel for application in spinal surgery.

Dong R, Zheng S, Cheng X Mater Today Bio. 2025; 31:101536.

PMID: 39990734 PMC: 11847550. DOI: 10.1016/j.mtbio.2025.101536.


The value of fixed segment mobility in posterior dynamic stabilization: a single-center retrospective study.

Sun Y, Guan J, Chen H, Sun X, Yang K, Fang Q BMC Musculoskelet Disord. 2025; 26(1):96.

PMID: 39893433 PMC: 11786513. DOI: 10.1186/s12891-025-08333-4.


References
1.
Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C . The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014; 73(6):968-74. DOI: 10.1136/annrheumdis-2013-204428. View

2.
Dagenais S, Caro J, Haldeman S . A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J. 2008; 8(1):8-20. DOI: 10.1016/j.spinee.2007.10.005. View

3.
Katz J . Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. J Bone Joint Surg Am. 2006; 88 Suppl 2:21-4. DOI: 10.2106/JBJS.E.01273. View

4.
Guo H, Tanaka S, Halperin W, Cameron L . Back pain prevalence in US industry and estimates of lost workdays. Am J Public Health. 1999; 89(7):1029-35. PMC: 1508850. DOI: 10.2105/ajph.89.7.1029. View

5.
Hartvigsen J, Hancock M, Kongsted A, Louw Q, Ferreira M, Genevay S . What low back pain is and why we need to pay attention. Lancet. 2018; 391(10137):2356-2367. DOI: 10.1016/S0140-6736(18)30480-X. View